A new preprint study suggests that Moderna’s COVID-19 vaccine may be significantly more effective against symptomatic disease from the delta variant compared to Pfizer-BioNTech’s vaccine, while the ...

Moderna on Tuesday released preliminary data indicating its vaccine is likely to hold up against several variants of concern, including the Delta variant, which is predicted to become the dominant ...

Moderna says its vaccine is 93% effective against symptomatic illness at six months (though this data collection ended before delta emerged in the U.S.). Moderna said its booster candidates also ...

Moderna hopes to offer updated COVID-19 boosters in the fall that combine its original vaccine with protection against the omicron variant. On Tuesday, it reported a preliminary hint that such an ...

Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data ...

Moderna said its COVID-19 vaccine demonstrated 93 percent efficacy, with efficacy remaining durable through six months after the second dose’s administration. The announcement was based on a new ...

Each week, we offer you a round-up of our noteworthy coronavirus coverage. More than 33.6 million people in the United States have tested positive for the coronavirus as of Friday morning, July 2, ...

Currently, the COVID-19 Delta variant has been reported in 60 countries and accounts for less than 6 percent of COVID-19 cases in the U.S. After months of steady decline in COVID-19 cases, the United ...

If COVID-19 booster shots become an annual precaution, the same way we get a flu shot every year, the next one may be formulated differently. Moderna and Pfizer working on a bivalent vaccine that ...

Neutralizing antibody levels rose 37-fold one month after the booster was given. Moderna announced Monday that its COVID-19 vaccine booster increases antibody levels against the omicron variant within ...